Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Elevance Health Inc. debt to equity ratio improved from Q2 2024 to Q3 2024 but then deteriorated significantly from Q3 2024 to Q4 2024. |
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Elevance Health Inc. debt to capital ratio improved from Q2 2024 to Q3 2024 but then deteriorated significantly from Q3 2024 to Q4 2024. |
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Elevance Health Inc. debt to assets ratio improved from Q2 2024 to Q3 2024 but then deteriorated significantly from Q3 2024 to Q4 2024. |
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Elevance Health Inc. financial leverage ratio decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 exceeding Q2 2024 level. |
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Elevance Health Inc. interest coverage ratio deteriorated from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
Debt to Equity
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Short-term borrowings | 365) | 360) | 225) | 1,575) | 225) | —) | 265) | 265) | 265) | 265) | 175) | 275) | 275) | 175) | 175) | —) | —) | 150) | —) | 1,075) | ||||||
Current portion of long-term debt | 1,649) | 2,100) | 2,900) | 2,900) | 1,649) | 799) | —) | —) | 1,500) | 2,249) | 2,248) | 3,097) | 1,599) | 849) | 849) | 700) | 700) | 1,599) | 1,603) | 1,603) | ||||||
Long-term debt, less current portion | 29,218) | 24,688) | 24,561) | 21,976) | 23,246) | 24,045) | 24,859) | 25,201) | 22,349) | 21,258) | 21,165) | 19,883) | 21,157) | 21,761) | 22,217) | 22,534) | 19,335) | 19,094) | 19,873) | 19,005) | ||||||
Total debt | 31,232) | 27,148) | 27,686) | 26,451) | 25,120) | 24,844) | 25,124) | 25,466) | 24,114) | 23,772) | 23,588) | 23,255) | 23,031) | 22,785) | 23,241) | 23,234) | 20,035) | 20,843) | 21,476) | 21,683) | ||||||
Shareholders’ equity | 41,315) | 43,775) | 42,191) | 40,608) | 39,306) | 38,423) | 38,205) | 37,356) | 36,307) | 35,991) | 35,812) | 35,975) | 36,060) | 35,737) | 34,968) | 33,853) | 33,199) | 33,921) | 34,455) | 31,693) | ||||||
Solvency Ratio | ||||||||||||||||||||||||||
Debt to equity1 | 0.76 | 0.62 | 0.66 | 0.65 | 0.64 | 0.65 | 0.66 | 0.68 | 0.66 | 0.66 | 0.66 | 0.65 | 0.64 | 0.64 | 0.66 | 0.69 | 0.60 | 0.61 | 0.62 | 0.68 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Debt to Equity, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 0.30 | 0.38 | 0.38 | 0.38 | 0.38 | 0.41 | 0.45 | 0.46 | 0.46 | 0.46 | 0.46 | 0.48 | 0.50 | 0.53 | 0.55 | 0.55 | 0.57 | 0.59 | 0.64 | 0.60 | ||||||
Cigna Group | 0.78 | 0.78 | 0.77 | 0.80 | 0.67 | 0.68 | 0.72 | 0.73 | 0.69 | 0.70 | 0.73 | 0.72 | 0.71 | 0.72 | 0.68 | 0.66 | 0.65 | 0.75 | 0.77 | 0.81 | ||||||
CVS Health Corp. | 0.88 | 0.87 | 0.89 | 0.87 | 0.81 | 0.83 | 0.88 | 0.82 | 0.74 | 0.74 | 0.73 | 0.76 | 0.75 | 0.79 | 0.81 | 0.87 | 0.93 | 0.97 | 1.05 | 1.10 | ||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
Medtronic PLC | 0.50 | 0.49 | 0.49 | 0.49 | 0.47 | 0.55 | 0.51 | 0.44 | 0.46 | 0.48 | 0.49 | 0.50 | 0.51 | 0.60 | 0.60 | 0.57 | 0.49 | 0.49 | 0.51 | 0.52 | ||||||
UnitedHealth Group Inc. | 0.83 | 0.83 | 0.84 | 0.85 | 0.70 | 0.75 | 0.80 | 0.87 | 0.74 | 0.65 | 0.71 | 0.65 | 0.64 | 0.67 | 0.70 | 0.70 | 0.66 | 0.67 | 0.72 | 0.91 |
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= 31,232 ÷ 41,315 = 0.76
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Elevance Health Inc. debt to equity ratio improved from Q2 2024 to Q3 2024 but then deteriorated significantly from Q3 2024 to Q4 2024. |
Debt to Capital
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Short-term borrowings | 365) | 360) | 225) | 1,575) | 225) | —) | 265) | 265) | 265) | 265) | 175) | 275) | 275) | 175) | 175) | —) | —) | 150) | —) | 1,075) | ||||||
Current portion of long-term debt | 1,649) | 2,100) | 2,900) | 2,900) | 1,649) | 799) | —) | —) | 1,500) | 2,249) | 2,248) | 3,097) | 1,599) | 849) | 849) | 700) | 700) | 1,599) | 1,603) | 1,603) | ||||||
Long-term debt, less current portion | 29,218) | 24,688) | 24,561) | 21,976) | 23,246) | 24,045) | 24,859) | 25,201) | 22,349) | 21,258) | 21,165) | 19,883) | 21,157) | 21,761) | 22,217) | 22,534) | 19,335) | 19,094) | 19,873) | 19,005) | ||||||
Total debt | 31,232) | 27,148) | 27,686) | 26,451) | 25,120) | 24,844) | 25,124) | 25,466) | 24,114) | 23,772) | 23,588) | 23,255) | 23,031) | 22,785) | 23,241) | 23,234) | 20,035) | 20,843) | 21,476) | 21,683) | ||||||
Shareholders’ equity | 41,315) | 43,775) | 42,191) | 40,608) | 39,306) | 38,423) | 38,205) | 37,356) | 36,307) | 35,991) | 35,812) | 35,975) | 36,060) | 35,737) | 34,968) | 33,853) | 33,199) | 33,921) | 34,455) | 31,693) | ||||||
Total capital | 72,547) | 70,923) | 69,877) | 67,059) | 64,426) | 63,267) | 63,329) | 62,822) | 60,421) | 59,763) | 59,400) | 59,230) | 59,091) | 58,522) | 58,209) | 57,087) | 53,234) | 54,764) | 55,931) | 53,376) | ||||||
Solvency Ratio | ||||||||||||||||||||||||||
Debt to capital1 | 0.43 | 0.38 | 0.40 | 0.39 | 0.39 | 0.39 | 0.40 | 0.41 | 0.40 | 0.40 | 0.40 | 0.39 | 0.39 | 0.39 | 0.40 | 0.41 | 0.38 | 0.38 | 0.38 | 0.41 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Debt to Capital, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 0.23 | 0.27 | 0.27 | 0.27 | 0.28 | 0.29 | 0.31 | 0.31 | 0.31 | 0.32 | 0.31 | 0.33 | 0.34 | 0.35 | 0.35 | 0.35 | 0.36 | 0.37 | 0.39 | 0.38 | ||||||
Cigna Group | 0.44 | 0.44 | 0.44 | 0.44 | 0.40 | 0.41 | 0.42 | 0.42 | 0.41 | 0.41 | 0.42 | 0.42 | 0.42 | 0.42 | 0.40 | 0.40 | 0.40 | 0.43 | 0.44 | 0.45 | ||||||
CVS Health Corp. | 0.47 | 0.47 | 0.47 | 0.46 | 0.45 | 0.45 | 0.47 | 0.45 | 0.42 | 0.42 | 0.42 | 0.43 | 0.43 | 0.44 | 0.45 | 0.47 | 0.48 | 0.49 | 0.51 | 0.52 | ||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
Medtronic PLC | 0.33 | 0.33 | 0.33 | 0.33 | 0.32 | 0.35 | 0.34 | 0.31 | 0.31 | 0.32 | 0.33 | 0.34 | 0.34 | 0.37 | 0.37 | 0.36 | 0.33 | 0.33 | 0.34 | 0.34 | ||||||
UnitedHealth Group Inc. | 0.45 | 0.45 | 0.46 | 0.46 | 0.41 | 0.43 | 0.44 | 0.46 | 0.43 | 0.39 | 0.41 | 0.39 | 0.39 | 0.40 | 0.41 | 0.41 | 0.40 | 0.40 | 0.42 | 0.48 |
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Debt to capital = Total debt ÷ Total capital
= 31,232 ÷ 72,547 = 0.43
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Elevance Health Inc. debt to capital ratio improved from Q2 2024 to Q3 2024 but then deteriorated significantly from Q3 2024 to Q4 2024. |
Debt to Assets
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Short-term borrowings | 365) | 360) | 225) | 1,575) | 225) | —) | 265) | 265) | 265) | 265) | 175) | 275) | 275) | 175) | 175) | —) | —) | 150) | —) | 1,075) | ||||||
Current portion of long-term debt | 1,649) | 2,100) | 2,900) | 2,900) | 1,649) | 799) | —) | —) | 1,500) | 2,249) | 2,248) | 3,097) | 1,599) | 849) | 849) | 700) | 700) | 1,599) | 1,603) | 1,603) | ||||||
Long-term debt, less current portion | 29,218) | 24,688) | 24,561) | 21,976) | 23,246) | 24,045) | 24,859) | 25,201) | 22,349) | 21,258) | 21,165) | 19,883) | 21,157) | 21,761) | 22,217) | 22,534) | 19,335) | 19,094) | 19,873) | 19,005) | ||||||
Total debt | 31,232) | 27,148) | 27,686) | 26,451) | 25,120) | 24,844) | 25,124) | 25,466) | 24,114) | 23,772) | 23,588) | 23,255) | 23,031) | 22,785) | 23,241) | 23,234) | 20,035) | 20,843) | 21,476) | 21,683) | ||||||
Total assets | 116,889) | 116,533) | 112,988) | 111,894) | 108,928) | 110,478) | 109,168) | 109,040) | 102,772) | 103,026) | 100,877) | 100,486) | 97,460) | 98,060) | 96,097) | 95,683) | 86,615) | 86,574) | 87,976) | 82,399) | ||||||
Solvency Ratio | ||||||||||||||||||||||||||
Debt to assets1 | 0.27 | 0.23 | 0.25 | 0.24 | 0.23 | 0.22 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.24 | 0.23 | 0.24 | 0.24 | 0.23 | 0.24 | 0.24 | 0.26 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Debt to Assets, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 0.17 | 0.20 | 0.20 | 0.20 | 0.20 | 0.22 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.24 | 0.25 | 0.25 | 0.25 | 0.26 | 0.27 | 0.29 | 0.27 | ||||||
Cigna Group | 0.21 | 0.21 | 0.21 | 0.21 | 0.20 | 0.21 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.21 | 0.21 | 0.21 | 0.22 | 0.23 | 0.24 | ||||||
CVS Health Corp. | 0.26 | 0.26 | 0.26 | 0.26 | 0.25 | 0.25 | 0.26 | 0.24 | 0.23 | 0.23 | 0.24 | 0.24 | 0.24 | 0.25 | 0.26 | 0.27 | 0.28 | 0.29 | 0.30 | 0.31 | ||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
Medtronic PLC | 0.28 | 0.28 | 0.28 | 0.28 | 0.27 | 0.30 | 0.29 | 0.26 | 0.27 | 0.27 | 0.28 | 0.28 | 0.28 | 0.31 | 0.31 | 0.31 | 0.27 | 0.28 | 0.28 | 0.29 | ||||||
UnitedHealth Group Inc. | 0.26 | 0.26 | 0.26 | 0.26 | 0.23 | 0.22 | 0.23 | 0.25 | 0.23 | 0.20 | 0.22 | 0.21 | 0.22 | 0.22 | 0.23 | 0.23 | 0.22 | 0.23 | 0.24 | 0.27 |
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Debt to assets = Total debt ÷ Total assets
= 31,232 ÷ 116,889 = 0.27
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Elevance Health Inc. debt to assets ratio improved from Q2 2024 to Q3 2024 but then deteriorated significantly from Q3 2024 to Q4 2024. |
Financial Leverage
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Total assets | 116,889) | 116,533) | 112,988) | 111,894) | 108,928) | 110,478) | 109,168) | 109,040) | 102,772) | 103,026) | 100,877) | 100,486) | 97,460) | 98,060) | 96,097) | 95,683) | 86,615) | 86,574) | 87,976) | 82,399) | ||||||
Shareholders’ equity | 41,315) | 43,775) | 42,191) | 40,608) | 39,306) | 38,423) | 38,205) | 37,356) | 36,307) | 35,991) | 35,812) | 35,975) | 36,060) | 35,737) | 34,968) | 33,853) | 33,199) | 33,921) | 34,455) | 31,693) | ||||||
Solvency Ratio | ||||||||||||||||||||||||||
Financial leverage1 | 2.83 | 2.66 | 2.68 | 2.76 | 2.77 | 2.88 | 2.86 | 2.92 | 2.83 | 2.86 | 2.82 | 2.79 | 2.70 | 2.74 | 2.75 | 2.83 | 2.61 | 2.55 | 2.55 | 2.60 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Financial Leverage, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 1.71 | 1.87 | 1.86 | 1.87 | 1.90 | 1.92 | 1.97 | 1.99 | 2.03 | 2.04 | 2.03 | 2.09 | 2.10 | 2.14 | 2.17 | 2.17 | 2.21 | 2.20 | 2.25 | 2.21 | ||||||
Cigna Group | 3.80 | 3.74 | 3.76 | 3.72 | 3.30 | 3.28 | 3.30 | 3.33 | 3.21 | 3.20 | 3.33 | 3.31 | 3.29 | 3.25 | 3.17 | 3.16 | 3.09 | 3.33 | 3.37 | 3.43 | ||||||
CVS Health Corp. | 3.35 | 3.37 | 3.37 | 3.38 | 3.27 | 3.38 | 3.44 | 3.35 | 3.21 | 3.27 | 3.06 | 3.15 | 3.10 | 3.16 | 3.16 | 3.24 | 3.32 | 3.38 | 3.46 | 3.54 | ||||||
Intuitive Surgical Inc. | 1.14 | 1.14 | 1.13 | 1.13 | 1.16 | 1.17 | 1.17 | 1.16 | 1.17 | 1.15 | 1.14 | 1.13 | 1.14 | 1.13 | 1.13 | 1.14 | 1.15 | 1.15 | 1.16 | 1.16 | ||||||
Medtronic PLC | 1.79 | 1.75 | 1.75 | 1.77 | 1.77 | 1.83 | 1.80 | 1.71 | 1.73 | 1.75 | 1.76 | 1.78 | 1.81 | 1.92 | 1.91 | 1.87 | 1.79 | 1.79 | 1.80 | 1.81 | ||||||
UnitedHealth Group Inc. | 3.22 | 3.17 | 3.20 | 3.28 | 3.08 | 3.34 | 3.40 | 3.49 | 3.16 | 3.26 | 3.16 | 3.04 | 2.96 | 3.03 | 3.05 | 3.09 | 3.01 | 2.93 | 3.03 | 3.32 |
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= 116,889 ÷ 41,315 = 2.83
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Elevance Health Inc. financial leverage ratio decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 exceeding Q2 2024 level. |
Interest Coverage
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Shareholders’ net income | 418) | 1,016) | 2,300) | 2,246) | 856) | 1,289) | 1,853) | 1,989) | 949) | 1,618) | 1,653) | 1,805) | 1,137) | 1,509) | 1,793) | 1,665) | 551) | 222) | 2,276) | 1,523) | ||||||
Add: Net income attributable to noncontrolling interest | (5) | (8) | 1) | 3) | (25) | 11) | 3) | 15) | 12) | (5) | (3) | (10) | (12) | (7) | 8) | 2) | —) | —) | —) | —) | ||||||
Add: Income tax expense | 193) | 365) | 685) | 690) | 170) | 354) | 585) | 615) | 193) | 533) | 493) | 531) | 275) | 494) | 552) | 509) | 60) | 167) | 873) | 566) | ||||||
Add: Interest expense | 340) | 300) | 280) | 265) | 259) | 259) | 261) | 251) | 229) | 213) | 208) | 201) | 200) | 201) | 205) | 192) | 191) | 198) | 201) | 194) | ||||||
Earnings before interest and tax (EBIT) | 946) | 1,673) | 3,266) | 3,204) | 1,260) | 1,913) | 2,702) | 2,870) | 1,383) | 2,359) | 2,351) | 2,527) | 1,600) | 2,197) | 2,558) | 2,368) | 802) | 587) | 3,350) | 2,283) | ||||||
Solvency Ratio | ||||||||||||||||||||||||||
Interest coverage1 | 7.67 | 8.52 | 9.07 | 8.70 | 8.49 | 8.87 | 9.76 | 9.95 | 10.13 | 10.75 | 10.71 | 11.01 | 10.93 | 10.04 | 8.03 | 9.09 | 8.96 | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
Interest Coverage, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 13.55 | 12.65 | 11.74 | 11.46 | 11.46 | 10.79 | 11.34 | 13.06 | 15.89 | 18.41 | 20.07 | 18.10 | 16.41 | 16.38 | 14.28 | 12.77 | 10.10 | — | — | — | ||||||
CVS Health Corp. | 3.08 | 3.33 | 4.41 | 4.55 | 5.20 | 5.59 | 2.71 | 3.43 | 3.46 | 2.75 | 5.49 | 5.27 | 5.16 | 4.92 | 4.60 | 4.52 | 4.36 | — | — | — | ||||||
Medtronic PLC | 7.73 | 8.87 | 8.97 | 9.90 | 9.43 | 10.15 | 11.02 | 10.88 | 10.98 | 10.95 | 10.18 | 5.65 | 5.21 | 3.68 | 4.02 | 6.60 | 4.71 | 4.12 | 3.84 | 3.76 | ||||||
UnitedHealth Group Inc. | 6.14 | 6.39 | 6.79 | 7.53 | 9.97 | 10.21 | 10.99 | 12.25 | 13.59 | 14.66 | 14.45 | 14.26 | 14.44 | 13.46 | 13.03 | 14.88 | 13.47 | — | — | — |
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Interest coverage
= (EBITQ4 2024
+ EBITQ3 2024
+ EBITQ2 2024
+ EBITQ1 2024)
÷ (Interest expenseQ4 2024
+ Interest expenseQ3 2024
+ Interest expenseQ2 2024
+ Interest expenseQ1 2024)
= (946 + 1,673 + 3,266 + 3,204)
÷ (340 + 300 + 280 + 265)
= 7.67
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Elevance Health Inc. interest coverage ratio deteriorated from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |